GNH USA

Europe — EMA

Meropenem Enexi (Meropenem Anhydrous)

GNH USA supplies Meropenem Enexi (Meropenem), a carbapenem antibiotic for intra‑abdominal infections, pneumonia and meningitis. Request a quote.

Meropenem Anhydrous

Request sourcing

1
Pack/s

What is Meropenem Anhydrous?

Meropenem, the active ingredient in Meropenem Enexi, is a carbapenem antibiotic presented as an intravenous powder for reconstitution for use in severe bacterial infections. It is indicated for a range of serious infections in hospitalized patients, including intra‑abdominal, urinary, pulmonary, bloodstream and central nervous system infections. GNH USA supplies Meropenem Enexi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

What is Meropenem Anhydrous used for?

Meropenem Enexi is a broad‑spectrum carbapenem used to treat infections caused by susceptible bacteria in several organ systems.

Complicated intra‑abdominal infections: provides rapid bacterial eradication and clinical cure. Complicated urinary tract infections: eliminates resistant Gram‑negative pathogens. Hospital‑acquired pneumonia: achieves high lung tissue concentrations for effective therapy. Septicemia: offers bactericidal activity against bloodstream infections. Meningitis: penetrates the cerebrospinal fluid to treat central nervous system infections.

What are the side effects of Meropenem Anhydrous?

Adverse reactions may occur with any antimicrobial therapy and should be monitored.

Common Side Effects: - Nausea or vomiting - Diarrhea, including mild Clostridioides difficile colonisation - Rash or mild skin erythema - Headache - Elevated liver enzymes - Injection‑site phlebitis or discomfort

Serious or Rare Side Effects: - Seizures, especially in patients with renal impairment - Severe Clostridioides difficile‑associated colitis - Anaphylactic or anaphylactoid reactions - Acute renal failure or worsening renal function - Hematologic abnormalities such as neutropenia or thrombocytopenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis

What precautions apply to Meropenem Anhydrous?

Use meropenem with careful clinical assessment and monitoring.

Renal impairment: adjust dose based on creatinine clearance. Seizure risk: avoid in patients with a history of epilepsy or CNS disorders. Hypersensitivity: discontinue if allergic reactions develop. Antimicrobial stewardship: limit use to confirmed susceptible infections. Pregnancy and lactation: weigh benefits against potential risks; consult specialist. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

What does Meropenem Anhydrous interact with?

Meropenem may alter the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Valproic acid: carbapenems reduce serum valproate levels, risking seizure breakthrough. - Oral contraceptives: may decrease hormonal efficacy, leading to unintended pregnancy. - Probenecid: can increase meropenem plasma concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Loop diuretics: combined nephrotoxic potential requires renal function monitoring. - Aminoglycosides: additive renal toxicity; adjust dosing and monitor creatinine.

Frequently asked questions

What infections is Meropenem Enexi used to treat?+
Meropenem Enexi is indicated for serious bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired pneumonia, septicemia, and bacterial meningitis. It is reserved for cases where the causative organisms are known or suspected to be susceptible to carbapenems.
How does meropenem work to eliminate bacteria?+
Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, preventing the cross‑linking of peptidoglycan strands. This leads to weakened cell walls, osmotic instability, and ultimately bacterial cell lysis and death.
What is the usual dose of Meropenem Enexi?+
The dosing regimen for Meropenem Enexi is determined by the prescribing clinician based on infection severity, site, pathogen susceptibility, and patient factors such as renal function. Only a qualified health professional should set the dose.
Is Meropenem Enexi safe to use during pregnancy or breastfeeding?+
Safety data for meropenem in pregnancy and lactation are limited. Use is only recommended when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and should be decided by a specialist obstetrician or pediatrician.
How do I order Meropenem Enexi from GNH USA?+
To place an order, submit an enquiry on the Meropenem Enexi product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does Meropenem compare with other carbapenems such as imipenem?+
Meropenem offers a broader spectrum against Gram‑negative organisms, including Pseudomonas aeruginosa, and has a lower propensity for inducing seizures compared with imipenem. Both belong to the carbapenem class, but selection depends on local susceptibility patterns, patient renal function and safety considerations.
What are the recommended storage conditions for Meropenem Enexi?+
Meropenem Enexi should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen. Once reconstituted, the solution should be used within the time frame specified in the product labeling and kept at controlled room temperature if required.
How is Meropenem Enexi administered to patients?+
Meropenem Enexi is supplied as a sterile powder for intravenous infusion. The powder is reconstituted with the appropriate diluent, then administered over 15‑30 minutes or as a continuous infusion, according to the prescribing clinician’s instructions.
What are the most serious risks associated with Meropenem Enexi?+
Serious adverse events include seizures (particularly in patients with renal impairment), severe Clostridioides difficile‑associated colitis, anaphylaxis, acute renal failure, and rare severe skin reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if any of these occur.
Who should not receive Meropenem Enexi?+
Meropenem Enexi is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Caution is also advised for patients with a history of seizures, severe renal impairment, or those receiving interacting medications without appropriate monitoring.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Meropenem Anhydrous
Route
Intravenous Use
Manufacturer
Nexcape Pharmaceuticals Limited
Origin
EU

Related products

Agenor

Agenor

Meropenem Anhydrous

Medochemie Ltd.
EU
Agenorem

Agenorem

Meropenem Anhydrous

Medochemie Ltd.
EU
Archifar

Archifar

Meropenem Anhydrous

Medochemie Ltd.
EU
Archifar

Archifar

Meropenem Anhydrous

Medochemie Ltd.
EU